Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback